AbbVie Inc.

New York Stock Exchange
Back to all articles
Somewhat Bullish +45

Chicago Partners Investment Group LLC Grows Holdings in AbbVie Inc ...

📈 Chicago Partners Investment Group LLC increased its ABBV holdings by 13.4% in Q1, adding 6,927 shares to a total stake of 58,582 shares.

📈 Worldquant Millennium Advisors LLC significantly grew its position by 117.3% in Q2, purchasing an additional 612,702 shares valued at $210.6 million.

📈 Revolve Wealth Partners LLC boosted its stake by 72.7% in Q4, acquiring 3,064 shares worth $1.29 million.

💰 AbbVie reported Q1 revenue of $15 billion, a 12.4% increase year-over-year that beat the consensus estimate of $14.72 billion.

📊 The company posted EPS of $2.65 for the quarter, surpassing analyst expectations of $2.59 by $0.06.

💸 AbbVie announced a quarterly dividend of $1.73 per share to be paid on August 14th with an ex-dividend date of July 15th.

⚠️ The company's dividend payout ratio is extremely high at 340.89%, suggesting the dividend is not fully covered by current earnings.

📉 AbbVie trades at a premium valuation with a price-to-earnings ratio of 122.17 and a negative return on equity of -576.45%.

🏢 Institutional investors collectively own 70.23% of the company's outstanding stock, indicating strong institutional confidence.

🔬 AbbVie focuses its operations on complex medical conditions across immunology, oncology, neuroscience, virology, and women's health.

Bullish Signals
  • AbbVie beat analyst earnings estimates with $2.65 EPS versus a consensus of $2.59, demonstrating operational strength.
  • Revenue grew by 12.4% year-over-year to reach $15 billion, exceeding the market expectation of $14.72 billion.
  • Multiple prominent hedge funds, including Worldquant Millennium Advisors and Chicago Partners, have increased their stakes in the stock.
  • The company maintains a consistent dividend policy with a declared payout of $1.73 per share for the upcoming quarter.
Risk Factors
  • AbbVie reports a negative return on equity of -576.45%, indicating significant leverage or capital structure challenges.
  • The dividend payout ratio stands at 340.89%, which is unsustainable based on current earnings and relies on other capital sources.
  • The stock trades at a very high price-to-earnings ratio of 122.17, suggesting the market prices in significant future growth or faces valuation risks.
Full Analysis
Institutional investors have increased their stakes in AbbVie Inc. (NYSE: ABBV) during the first and second quarters of 2026, signaling renewed interest from hedge funds. Chicago Partners Investment Group LLC raised its position by 13.4% to own 58,582 shares valued at $11.7 million in Q1. Other notable increases include Worldquant Millennium Advisors LLC, which surged its holdings by 117.3% to acquire over 612,000 shares worth $210.6 million in Q2, and Revolve Wealth Partners LLC, which boosted its stake by 72.7%. AbbVie recently reported strong quarterly financial results for the period ending April 29th, beating analyst expectations on both earnings per share and revenue. The company posted $2.65 EPS compared to a consensus of $2.59, driven by revenue of $15 billion which represented a 12.4% year-over-year increase. Despite the positive earnings beat, the stock trades at a high valuation with a price-to-earnings ratio of 122.17 and a negative return on equity of -576.45%, reflecting market concerns regarding its financial structure. The biopharmaceutical giant also announced a quarterly dividend to be paid on August 14th for shareholders of record on July 15th. The payout amounts to $1.73 per share, representing an annualized yield of 2.8%. However, the company's dividend payout ratio is exceptionally high at 340.89%, indicating that the dividend is being funded from sources other than current earnings. AbbVie continues to focus on its portfolio in immunology, oncology, and neuroscience as it navigates these financial dynamics.